Edesa Biotech, Inc. 8-K

What Happened
Edesa Biotech, Inc. (EDSA) announced its quarterly financial results via a press release dated February 13, 2026, covering the three months ended December 31, 2025. The press release (the "Earnings Release") is attached to the Form 8-K as Exhibit 99.1. The company notes the information is furnished (not filed) under the Exchange Act and therefore is not subject to Section 18 liability.

Key Details

• Press release announcing quarterly results issued on February 13, 2026.
• Results cover the three months ended December 31, 2025.
• Earnings Release is attached as Exhibit 99.1 to the Form 8-K.
• Form 8-K was signed by Peter J. Weiler, Chief Financial Officer; information furnished (not filed).

Why It Matters
This 8-K signals that Edesa has publicly reported its latest quarterly earnings and financial condition; investors should read the attached Earnings Release for revenue, profit/loss, cash position, and any commentary on operations or outlook. Because the release is furnished rather than filed, the company limits certain legal liabilities under the Exchange Act; substantive financial details and implications for valuation will be in the attached press release and any subsequent filed reports (e.g., 10-Q).